<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is a diverse group of clonal hematologic <z:hpo ids='HP_0002664'>neoplasms</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Different medications have been tried in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; however, no effective treatment has been yet established </plain></SENT>
<SENT sid="2" pm="."><plain>We report a patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> who achieved a complete remission in response to combination therapy of <z:chebi fb="1" ids="4315">danazol</z:chebi>, <z:chebi fb="2" ids="26536">retinoic acid</z:chebi>, and <z:chebi fb="0" ids="8382">prednisone</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>A 53-year-old female presented with <z:hpo ids='HP_0001876'>pancytopenia</z:hpo>, <z:mp ids='MP_0000248'>macrocytosis</z:mp>, and hypercellular bone marrow with <z:hpo ids='HP_0012132'>erythroid hyperplasia</z:hpo> and <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and 10% ringed sideroblasts </plain></SENT>
<SENT sid="4" pm="."><plain>Cytogenetic studies revealed the presence of two abnormal clones </plain></SENT>
<SENT sid="5" pm="."><plain>She was diagnosed as having <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:hpo ids='HP_0005505'>refractory anemia</z:hpo> and was given blood transfusions to maintain blood cell counts at acceptable levels </plain></SENT>
<SENT sid="6" pm="."><plain>At the same time, she was started on a combination of <z:chebi fb="1" ids="4315">danazol</z:chebi> (600 mg/day), <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> (100 mg/day), and <z:chebi fb="0" ids="8382">prednisone</z:chebi> (10 mg every other day) </plain></SENT>
<SENT sid="7" pm="."><plain>Fourteen months later, the patient was in complete hematologic remission; she had <z:mpath ids='MPATH_458'>normal</z:mpath> peripheral blood count, and the blood smear showed <z:mpath ids='MPATH_458'>normal</z:mpath> <z:mp ids='MP_0000002'>morphology</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>Bone marrow studies revealed <z:mpath ids='MPATH_458'>normal</z:mpath> trilineage hematopoiesis </plain></SENT>
<SENT sid="9" pm="."><plain>She was continued on the same combination treatment for 86 months, and she remained in complete clinical remission </plain></SENT>
<SENT sid="10" pm="."><plain>Eighty-eight months from diagnosis, she relapsed with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>This is the first reported case of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RA that sustained a complete hematologic remission for a prolonged period in response to this combination treatment </plain></SENT>
<SENT sid="12" pm="."><plain>This report indicates that restoration of <z:mpath ids='MPATH_458'>normal</z:mpath> hematopoiesis, prolongation of disease-free survival, and delay in the transformation to <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> may be achieved by this combination of treatment in a subset of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, especially <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with severe <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> </plain></SENT>
</text></document>